Warning: file_get_contents(http://tehnika-news.ru/shells.txt): failed to open stream: HTTP request failed! HTTP/1.1 403 Forbidden in /var/sites/p/paperbomb.com/public_html/meds2/1/index.php on line 2
besponsa product monograph

besponsa product monograph

Перейти к контенту

Главное меню:

besponsa product monograph
Besponsa Monograph for Professionals - Drugs.com, Welcome to BESPONSA® | BESPONSA®, BESPONSA (inotuzumab ozogamicin) | Pfizer Canada, PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION - pfizer.ca, Besponsa for Acute Lymphoblastic Leukemia – Details | CADTH.ca, New Drug Product: Besponsa - MPR - empr.com, , , .
For serum ALT and/or AST concentrations >2.5 times the ULN or total bilirubin concentrations >1.5 times the ULN (except in patients with Gilbert’s syndrome or hemolysis), interrupt therapy until ALT and AST recover to ≤2.5 times the ULN and total bilirubin concentrations recover to ≤1.5 times the ULN.1 If therapy is withheld for <7 days, administer next dose upon resolution of toxicity; however, adjust administration schedule to maintain a minimum of 6 days between doses.1 5 If therapy is withheld for ≥7 days but <14 days, omit next dose.1 If therapy is withheld for ≥14 days, reduce dosage by 25% in subsequent cycles; if further dosage reduction is necessary, reduce frequency of administration in subsequent cycles from 3 to 2 doses per cycle.1 If dosage modification (dosage reduction or reduced frequency) is not tolerated or elevated ALT, AST, or total bilirubin concentrations persist for >28 days despite interruption of therapy, permanently discontinue drug.1. Besponsa reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI).. BESPONSA is a prescription medicine used to treat adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). It is not known if BESPONSA is safe and effective in children under 18 years of age..
Product Monograph (download PDF, 403KB) Patient Information (download PDF, 250KB) Canadian regulations limit the scope of information we are permitted to give on prescription drugs via the Internet or other means.. BESPONSATM Product Monograph Page 5 of 43 medical management. Depending on the severity of the infusion-related reaction, consider discontinuation of the infusion and/or administration of steroids and antihistamines.. ‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback.. This slideshow reviews drug information for Besponsa. Click here for the complete Besponsa new product monograph . For a downloadable PDF of this slideshow, click here .. . .
Copyright 2019. All rights reserved.
Назад к содержимому | Назад к главному меню